Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2024-03-25 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于子公司被纳入失信被执行人名单的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Biological Co., Ltd. regarding its subsidiary being listed as a dishonest executor (失信被执行人名单) by a court. It details the legal case, obligations, and the company's statement on the impact and ongoing communication. The document is short (832 characters) and serves as a regulatory disclosure about a legal and credit status issue, not a financial report or detailed audit. It does not contain financial statements, earnings data, or management discussion. It is a regulatory announcement about a legal matter affecting the company, fitting best under Legal Proceedings Report (LTR).
2024-03-25 Chinese
关于补选公司第十届监事会职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's supervisory board. It includes details about the individual's background and compliance with legal and regulatory requirements. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting or voting results. This fits the category of Board/Management Information, as it concerns changes in the company's supervisory board members.
2024-03-08 Chinese
江苏四环生物股份有限公司关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel, specifically the Chief Financial Officer. It details the resignation, the effective date, and interim arrangements for the role. There is no financial data, report, or presentation included. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2024-03-01 Chinese
江苏四环生物股份有限公司2023年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast (业绩预告) for Jiangsu Sihuan Bio, covering the full fiscal year 2023 (Jan 1 to Dec 31). It provides estimated net profit and earnings per share figures, indicating expected losses. The document explicitly states that the data is preliminary, unaudited, and subject to the final 2023 annual report. It also mentions communication with the audit firm but no audit has been completed yet. The document length is short (932 characters) and it is a forward-looking earnings forecast rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not a full annual report (10-K). FY 2023
2024-01-30 Chinese
江苏四环生物股份有限公司关于职工监事辞职的公告
Board/Management Information Classification · 95% confidence The document is a short announcement regarding the resignation of an employee supervisor (职工监事) from the company's supervisory board. It does not contain financial data, audit information, or details about management changes at the board or senior executive level. It is a regulatory announcement about a personnel change in the supervisory board, which fits best under Board/Management Information (MANG). The document length is very short (344 characters), and it is not a report or a report publication announcement. Therefore, the classification is MANG with high confidence.
2024-01-08 Chinese
关于实际控制人收到中国证券监督管理委员会立案告知书的公告
Regulatory Filings Classification · 100% confidence The document is an announcement from a company about its actual controller receiving a formal investigation notice from the China Securities Regulatory Commission regarding alleged disclosure violations. It states the investigation is related to the individual and not the company, and that the company will continue to disclose information as required. The document is short (558 characters) and serves as a regulatory update rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report content. This fits the definition of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2023-12-24 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.